Evidence map›Paper›PMID 39953553›Full record

ArticleMalaria journal2025

Unravelling the mode of action of the Tres Cantos Antimalarial Set (TCAMS): investigating the mechanism of potent antimalarial compounds potentially targeting the human serotonin receptor.

Benedito Matheus Dos Santos, Lenna Rosanie Cordero Mallaupoma, Mateus Fila Pecenin, Abhinab Mohanty, Angela Lu, Paula J Bartlett, Andrew P Thomas, Francisco-Javier Gamo, Celia R S Garcia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Benedito Matheus Dos SantosDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, 05508-000, Brazil.ORCID http://orcid.org/0000-0002-2196-260X
Lenna Rosanie Cordero MallaupomaDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, 05508-000, Brazil.
Mateus Fila PeceninDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, 05508-000, Brazil.ORCID http://orcid.org/0000-0001-5799-012X
Abhinab MohantyDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, 05508-000, Brazil.
Angela LuDepartment of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Rutgers University, Newark, NJ, 07103, USA.
Paula J BartlettDepartment of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Rutgers University, Newark, NJ, 07103, USA.ORCID http://orcid.org/0000-0002-4089-1288
Andrew P ThomasDepartment of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Rutgers University, Newark, NJ, 07103, USA.ORCID http://orcid.org/0000-0002-9026-7467
Francisco-Javier GamoGlobal Health Medicines R&D, GlaxoSmithKline (GSK), Tres Cantos, 28760, Madrid, Spain.ORCID http://orcid.org/0000-0002-1854-2882
Celia R S GarciaDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, 05508-000, Brazil. cgarcia@usp.br.ORCID http://orcid.org/0000-0003-2825-1701

Funding

CMV Vectored Herpes Simplex VaccineR41AI109927 · NIAID · TOMEGAVAX, INC. · PI STREBLOW, DANIEL N · 2014 to 2014
$300k
Conselho Nacional de Desenvolvimento Científico e Tecnológico 131146/2020-3Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/16483-6Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/08684-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/08988 - 9NIAID NIH HHS R41 AI109927NIH HHS R01 AI109927
6 · The paper itself

Abstract

backgroundDespite the strides made in recent decades, the resistance observed in existing antimalarial drugs, and the intricate life cycle of the Plasmodium parasite underscore the pressing need to develop novel and effective therapeutic interventions. This article provides a comprehensive evaluation of the outcomes stemming from screening a library comprising 48 compounds (TCAMS) against Plasmodium falciparum.

methodsThis study focused on characterizing the IC

resultsIC

conclusionsThis study identifies promising antimalarial candidates with low IC

Indexed as

AntimalarialsPlasmodium falciparumReceptors, SerotoninHEK293 CellsHumansInhibitory Concentration 50AntimalarialsReceptors, SerotoninAntimalarialMelatoninPlasmodium falciparumSerotoninTCAMS

Identifiers

PMID39953553
PMCPMC11827156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.